EML4 and lung cancer: Cells expressing STRN-ALK increased thyroid-stimulating, hormone-independent cell proliferation and developed tumours in nude mice.16 The ALK inhibitor, crizotinib, was approved by the US Food and Drug Administration as a chemotherapeutic treatment for lung cancer patients positive for EML4-ALK.